文献速递骨质疏松与钙磷/甲状旁腺性腺与生殖内分泌

抗苗勒管激素与I型胶原C端肽预测围绝经早期快速骨丢失:SWAN研究

Anti-Mullerian Hormone and Collagen Type I C-telopeptide Predict Fast, Imminent Bone Loss in Early Perimenopause: SWAN.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

基于SWAN社区队列436名早期围绝经期女性,采用重复测量改良泊松回归分析发现,较低的抗苗勒管激素(AMH)或较高的I型胶原C端肽(CTX)水平分别与未来1-2年内腰椎、股骨颈或全髋的快速骨密度丢失风险升高相关;联合AMH与CTX的模型预测效能优于单独使用任一指标。

要点

  • AMH每降低1个SD,快速腰椎骨丢失风险增加45%,股骨颈增加17%,全髋增加26%。
  • CTX每升高1个SD,快速腰椎骨丢失风险增加35%,股骨颈增加23%,全髋增加34%。

核心结论

  • 联合AMH与CTX比单独使用任一指标能更强地预测早期围绝经期女性未来1-2年内的快速骨密度丢失。

研究设计与样本

  • 研究为社区队列SWAN中的重复测量分析,共纳入436名早期围绝经期女性,采用改良泊松回归评估AMH和CTX与快速骨丢失的关联。

主要发现

  • 在分别调整年龄、BMI、吸烟、种族/民族和研究中心的独立模型中,较低AMH或较高CTX均与快速骨丢失风险升高相关。
  • 在同时纳入AMH和CTX的单一模型中,两者仍独立相关。

关键数值与推荐

  • 快速骨丢失定义为未来1-2年内骨密度下降速率≥平均年绝经率。

临床怎么用

  • 在早期围绝经期女性中,可考虑联合检测AMH和CTX以识别未来1-2年内快速骨丢失的高风险个体,辅助决定是否加强骨密度监测或干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Faster menopause-related bone mineral density (BMD) decline predicts more fractures. OBJECTIVE: Examine anti-Mullerian hormone (AMH) and collagen type I C-telopeptide (CTX) as predictors of fast, imminent BMD loss (BMD decline rate, over the next 1-2 years, ≥mean, annual menopause rate). DESIGN: Repeated measures modified Poisson regression estimated the associations of early perimenopausal levels of (1) AMH or CTX (in separate models), or (2) AMH and CTX (in a single model) with fast, imminent BMD loss. SETTING: Study of Women's Health Across the Nation (community-based cohort). PARTICIPANTS: A total of 436 early perimenopausal women. MAIN OUTCOME MEASURES: Fast, imminent BMD loss (at lumbar spine [LS], femoral neck [FN], or total hip [TH]). RESULTS: In separate models, adjusted for age, body mass index, cigarette use, race/ethnicity and study site, lesser AMH or greater CTX individually related to greater fast, imminent BMD loss risk. As predictors in a single model, lesser AMH and greater CTX remained independently associated with fast, imminent BMD loss. Per SD decrement in log-transformed AMH, fast BMD decline risk was 45% (LS), 17% (FN), and 26% (TH) greater (each P < .0001). Per SD increment in log-transformed CTX, fast BMD loss risk was 35% (LS), 23% (FN), and 34% (TH) greater (each P < .0001). Model areas under the curve was greater for models with AMH and CTX vs those for models with AMH or CTX individually (P < .001 for each BMD site-specific comparison). CONCLUSION: Combining AMH and CTX affords stronger prediction of fast, imminent BMD loss than using AMH or CTX individually.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Shieh A, Karlamangla AS, Gossiel F, et al. Anti-Mullerian Hormone and Collagen Type I C-telopeptide Predict Fast, Imminent Bone Loss in Early Perimenopause: SWAN. J Clin Endocrinol Metab. 2026. PMID: 41399290. doi:10.1210/clinem/dgaf658

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。